![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
An Open-Label Study to Evaluate the Efficacy and Safety of Co-Formulated Ombitasvir/Paritaprevir/Ritonavir With Ribavirin in Adults with Chronic HCV Genotype 4 Infection in Egypt (AGATE-II)
|
|
|
Reported by Jules Levin
EASL 2015 April 22-26 Vienna Austria
Wahid Doss1, Gamal Esmat2, Roula B Qaqish3, Imam Waked4, Gamal Shiha5, Ayman Yosry2, Jennifer King3, Coleen Hall3, Niloufar Mobashery3
1National Hepatology & Tropical Medicine Research Institute, Cairo, Egypt; 2Cairo University, Cairo, Egypt; 3AbbVie Inc., North Chicago, Illinois, USA; 4National Liver Institute, Menoufiya, Egypt; 5Egyptian Liver Research Institute and Hospital (ELRIAH), Dakahliah, Egypt
![EASL1.gif](../images/042415/042415-14/EASL1.gif)
![EASL2.gif](../images/042415/042415-14/EASL2.gif)
![EASL3.gif](../images/042415/042415-14/EASL3.gif)
![EASL4.gif](../images/042415/042415-14/EASL4.gif)
![EASL5.gif](../images/042415/042415-14/EASL5.gif)
![EASL6.gif](../images/042415/042415-14/EASL6.gif)
![EASL7.gif](../images/042415/042415-14/EASL7.gif)
![EASL8.gif](../images/042415/042415-14/EASL8.gif)
![EASL9.gif](../images/042415/042415-14/EASL9.gif)
![EASL10.gif](../images/042415/042415-14/EASL10.gif)
![EASL11.gif](../images/042415/042415-14/EASL11.gif)
![EASL12.gif](../images/042415/042415-14/EASL12.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|